The purpose of this study is to evaluate the safety, tolerability and effectiveness of Acthar to slow new muscle weakness in ALS.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study CEUAR.
Subjects with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, who are aged 75 years or less, have good breathing (VFC greater than 60%) and who have had weakness for less than 24 months.
June 01, 2018